Key result
Sarcoidosis is linked to a ~2-fold higher angiotensin I requirement for complete ACE inhibition.
Why the study?
Plasma converting enzyme activity may reflect pulmonary conversion and can be altered by pulmonary disease, but its measurement and implications require characterization.
How is plasma angiotensin I converting enzyme activity altered in patients with pulmonary diseases compared to normal subjects?
Observational (n=41)
How is plasma angiotensin I converting enzyme activity altered in patients with pulmonary diseases compared to normal subjects?
Plasma converting enzyme activity is altered by pulmonary disease, being increased in sarcoidosis and decreased in COPD and shock lung, suggesting its potential utility in studying the renin-angiotensin system.
Answers are grounded in this paper and cite their sources.
ACE activity may be elevated in sarcoidosis and reduced in COPD; hypothesis-generating for its utility in renin-angiotensin studies.
A specific method is described for the measurement of angiotensin I converting enzyme activity in plasma with 125 I-labelled angiotensin I used as substrate. 2. Converting enzyme activity in plasma from fifteen normal subjects, eleven patients with sarcoidosis, twelve patients with chronic obstructive pulmonary disease and three patients with shock lung was assayed by this technique. 3. Patients with sarcoidosis had increased plasma converting enzyme activity whether or not they were receiving steroid therapy. 4. Patients with chronic obstructive pulmonary disease and shock lung had decreased plasma converting enzyme activity, but extent of conversion did not correlate with the severity of the lung disease. 5. Converting enzyme activity in normal plasma could be completely inhibited by addition of exogenous angiotensin I in 0.5-2.5x107 times physiological concentration. Twice as much exogenous angiotensin I was needed to inhibit conversion completely in plasma from patients with sarcoidosis; one tenth as much in chronic obstructive pulmonary disease. These results indicate that plasma has a high capacity for angiotensin I conversion even in patients with pulmonary parenchymal disease. 6. Results suggest that plasma converting enzyme activity may be a reflection of pulmonary conversion and can be altered by pulmonary disease. 7. Measurement of plasma converting enzyme activity may be useful in studies designed to characterize the regulatory role of converting enzyme in the renin-angiotensin system and in cardiovascular homeostasis.
No takes yet. Share an insight, caveat, or question.
Oparil et al. (1976) conducted an observational in Pulmonary disease (sarcoidosis, chronic obstructive pulmonary disease, shock lung) (n=41). Pulmonary disease vs. Normal subjects was evaluated on Plasma angiotensin I converting enzyme activity. Patients with sarcoidosis required twice as much exogenous angiotensin I to completely inhibit plasma converting enzyme activity, while COPD patients required one tenth as much as normal subjects.
Synapse has enriched 10 related papers. Consider them for comparative context: